Compare AYTU & NBY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AYTU | NBY |
|---|---|---|
| Founded | N/A | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.4M | 31.6M |
| IPO Year | 2015 | 2007 |
| Metric | AYTU | NBY |
|---|---|---|
| Price | $2.21 | $1.95 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $9.33 | N/A |
| AVG Volume (30 Days) | 40.3K | ★ 608.2K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 35.42 |
| EPS | N/A | ★ 0.76 |
| Revenue | ★ $27,632,080.00 | $370,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $43.75 | N/A |
| P/E Ratio | ★ N/A | $2.57 |
| Revenue Growth | ★ 277.47 | N/A |
| 52 Week Low | $1.65 | $0.43 |
| 52 Week High | $3.07 | $19.95 |
| Indicator | AYTU | NBY |
|---|---|---|
| Relative Strength Index (RSI) | 42.64 | 57.82 |
| Support Level | $2.17 | $1.01 |
| Resistance Level | $2.30 | $2.52 |
| Average True Range (ATR) | 0.10 | 0.26 |
| MACD | 0.02 | 0.11 |
| Stochastic Oscillator | 41.94 | 96.45 |
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare, wound care, and skin care products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material, including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.